Asset Details
Do you wish to reserve the book?
Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease
Do you wish to request the book?
Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease
2014
Overview
Background
Urologists have not reached a consensus regarding the pre-, intra-, and postoperative management of patients taking antiplatelet agents. This study aimed to evaluate the clinical course of patients receiving antithrombotic monotherapy with acetylsalicylic acid (ASA) 100 mg who underwent transurethral resection of bladder cancer.
Methods
This study was designed to compare the surgical outcomes for 108 transurethral resections of bladder cancer performed for patients taking antiplatelet therapy and for 105 procedures performed for patients who had never taken antiplatelet agents before surgery. Antiaggregant therapy was maintained according to criteria evaluated by a urologist, surgeon, anesthesiologist, and cardiologist. Variables were described using the mean as the location index and using standard deviation as a dispersion index if continuous percentages were used elsewhere. Group comparisons were performed using the
t
test or the chi-square test for categorical data, and Fisher’s exact test was used where appropriate.
Results
The mean operative time for patients taking ASA was 31 min (range 10–65 min), whereas it was 26 min (range 5–60 min) for control subjects. The difference between pre- and postoperative hemoglobin values was −0.6 g/dl in the group receiving antiplatelet therapy and −0.8 g/dl in the control group (
p
= 0.0720). Transfusional support was required during four procedures performed for patients taking antiplatelet therapy and during two procedures for the control group (
p
= 0.242). No adverse cardiac events or anesthesia-related complications occurred. Three patients in the treatment group and two patients in the control group required reintervention to ensure hemostasis during the postoperative period. None of the patients in either group underwent rehospitalization for hematuria after leaving the hospital.
Conclusion
The current results suggest that continued use of anti-aggregant monotherapy does not increase the risk of overall bleeding or reintervention for patients undergoing transurethral resection of bladder neoplasms and that suspending aspirin before such a procedure is therefore unnecessary.
Publisher
Springer US,Springer Nature B.V
Subject
/ Aged
/ Aspirin
/ Cardiovascular Diseases - complications
/ Cardiovascular Diseases - drug therapy
/ Female
/ Hemorrhage - chemically induced
/ Hemorrhage - prevention & control
/ Humans
/ Male
/ Medicine
/ Platelet Aggregation Inhibitors - adverse effects
/ Platelet Aggregation Inhibitors - therapeutic use
/ Surgeons
/ Surgery
/ Tumors
/ Urinary Bladder Neoplasms - complications
/ Urinary Bladder Neoplasms - surgery
/ Urologic Surgical Procedures - adverse effects
/ Urology
